The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies. Daratumumab, a fully human monoclonal antibody targeting CD38, has shown clinical efficacy in relapsed/ refractory multiple myeloma both as monotherapy and in combination with other drugs, including novel agents. More recently, promising results have been reported in patients with untreated newly diagnosed multiple myeloma (NDMM). Clinical trials thus far have shown enhanced efficacy and tolerability of several daratumumab-based combinations in both transplant ineligible and eligible patients, without compromising transplant ability. However, benefit in high-risk subpopulations is still unclear. A subcutaneous formulation of daratumumab has been introduced to decrease the risk of infusion reactions, with preliminary results showing non-inferior efficacy. The antimyeloma activity of daratumumab is achieved through multiple mechanisms including direct, Fc-dependent, and immunomodulatory mechanisms. Enhanced efficacy of daratumumab in combination with immunomodulatory drugs and proteasome inhibitors is supported by preclinical data showing synergism. This review will focus on the role of daratumumab in untreated NDMM patients, highlighting the results of major clinical trials, and listing ongoing trials that are evaluating various daratumumab-based combinations in this setting.
Introduction
Multiple myeloma (MM) is a neoplastic clonal plasma cell disorder characterized by secretion of a monoclonal protein in the blood or urine and organ dysfunction manifesting as anemia, hypercalcemia, renal failure, and lytic bone lesions. 1 MM is more commonly diagnosed in men and older patients between the age of 65 and 74 years, and accounts for 1.8% of all new cancer cases in the US. 2 Treatment strategies in MM have evolved markedly in the past decade with the introduction of novel treatment agents. [3] [4] [5] This has expanded the treatment options for both newly diagnosed multiple myeloma (NDMM) and relapsed or refractory (R/R) disease. These include immunomodulatory drugs (IMiD) like thalidomide, lenalidomide, and pomalidomide; and proteasome inhibitors (PI) like bortezomib, carfilzomib, and ixazomib. The heterogeneity of drug classes and nonoverlapping mechanisms of action has allowed their use in combination to achieve greater responses. [3] [4] [5] In the absence of direct comparisons among all available combinations, the choice of initial treatment is currently guided by physician and patient preference, taking into account disease stage, transplant eligibility, risk stratification based on cytogenetic abnormalities, comorbidities, frailty, and functional status. 6 Despite advances in treatment, MM mortality remains high, with 5-year overall survival estimated at 52.2%. 2 This highlights the need for more effective therapeutic options. The CD38 targeted monoclonal antibody (mAb) daratumumab has shown clinical efficacy in R/R MM both as monotherapy, and in combination with other drugs, including novel agents, leading
The rationale for daratumumab-based combinations The benefit of adding daratumumab to other treatment regimens, particularly IMiD-and PI-based combinations, is supported by preclinical data. Daratumumab has exhibited synergistic effects in enhancing MM cell lysis ex vivo when combined with lenalidomide or bortezomib, particularly in the triplet combination. Interestingly, this effect was more pronounced in myeloma cells of patients who had low response or refractoriness to treatment with lenalidomide or bortezomib. 13 This implies that daratumumab may have the potential to reinstate the host susceptibility to these agents through its immunomodulating effects. 14 The ability of IMiDs, including thalidomide, lenalidomide, and pomalidomide, to activate immune effector cells like NK cells or reduce inhibitory T cell populations in vitro, may be a potential explanation for this synergism. 15 Lenalidomide, in particular, has been shown to augment daratumumab-induced myeloma cell lysis by ADCC by inducing endogenous NK cells, 14 and to potentiate ADCP by inducing endogenous macrophages through vitamin D pathway activation. 16 Furthermore, lenalidomide has the potential to sensitize Tregs to the action of daratumumab by upregulating CD38 expression on Tregs, and by increasing the fraction of CD38-high Tregs. 17 Lenalidomide has not been shown to influence complement-mediated cytotoxicity. 18 Role of daratumumab in R/R MM Since initial use in 2015, 19 there has been clear evidence for daratumumab efficacy in pretreated MM patients both as monotherapy and in combination with other agents. The GEN501 and SIRIUS trials provided the earliest reports on efficacy and safety of daratumumab as monotherapy in heavily pretreated R/R MM patients. A combined analysis showed durable responses after 36.6 months of median follow up, with an overall response rate (ORR) of 30.4%, median overall survival (OS) of 20.5 months (CI 16.6-28.1), and 3-year OS rate of 36.5% (28.4-44.6 ). [19] [20] [21] Results from these studies led to the approval of daratumumab monotherapy in patients with at least three lines of prior therapy including an IMiD and PI, or double refractory to an IMiD and PI. Evidence for clinical efficacy in combination with bortezomib and lenalidomide in R/R patients was provided by the CASTOR and POLLUX trials, respectively. 22, 23 In the CASTOR trial, the combination of daratumumab with bortezomib and dexamethasone (DVd) was superior to bortezomib and dexamethasone (Vd) alone, achieving significantly longer progression-free survival (PFS) (median PFS: 16.7 versus 7.1 months at 31.3 months median follow up) and superior overall and deeper responses, including minimal residual disease (MRD) negativity. 24 After showing safety and efficacy in the phase I/II GEN503 trial, 25, 26 the combination of daratumumab with journals.sagepub.com/home/tah 3 lenalidomide and dexamethasone (DRd) was found to be superior to lenalidomide and dexamethasone alone (Rd) in R/R MM in the phase III POLLUX trial. 23 The addition of daratumumab to Rd was associated with longer PFS; at a median follow up of 39.5 months, median PFS was NR versus 17.5 months with hazard ratio (HR) 0.44, 0.35-0.55 p < 0.0001. Similarly, greater overall and deeper responses were achieved, including significantly improved and sustained MRD negativity rate. 27 Together, these results lead to the approval of daratumumab in combination with Vd or Rd in R/R MM patients. 28 The combination of daratumumab, pomalidomide, and dexamethasone (Dara-Pom-Dex) has also gained FDA approval for use in R/R patients based on results from the EQUULEUS trial, showing an ORR of 60% and MRD negativity of 29%. 29 Interestingly, retreatment with the Dara-Pom combination in patients who were previously refractory to Dara or Pom was associated with response in a retrospective study. 30 This regimen is not yet approved for use in Europe and other countries outside the US. Encouraging results have also been reported for daratumumab in combination with carfilzomib and dexamethasone in R/R patients following one to three lines of therapy. 31
Role of daratumumab in untreated MM
The efficacy of daratumumab observed in R/R MM, particularly among patients with fewer lines of prior therapy, 24 has been replicated in untreated MM, expanding its labeled use to include transplant-ineligible NDMM. 32 This was based on results from the ALCYONE and MAIA trials, showing improved responses when daratumumab is combined with Rd or melphalan-bortezomibprednisone (MVP) respectively. 33, 34 In addition, encouraging results are being reported in other combinations with standard-of-care regimens, and deeper responses are being achieved even in transplant-eligible patients, without compromising the ability to proceed to transplant. We discuss below the most important clinical trials evaluating daratumumab combinations in NDMM.
Daratumumab in transplant-ineligible NDMM
The dosing and safety of daratumumab, in combination with standard regimens in NDMM patients, were established in a phase Ib trial where four different daratumumab-based combinations were used, including melphalan, bortezomib, thalidomide, and pomalidomide. 35 34 Based on results from these two trials, D-VMP has been approved in the US and Europe, and DRd has been approved only in the US, for use as first line treatments in transplant ineligible MM patients.
Given the lack of direct head-to-head comparisons, there is little evidence to guide treatment choice between the various standard regimens at this time. A recently published metanalysis by Cao and colleagues compared the efficacy of currently used treatment regimens in this group of patients using Rd as reference. In terms of PFS, three combinations showed superiority to Rd: DRd (HR: 0.57, 0.43-0.73), D-VMP (HR, 0.59, 0.36-0.91), and VRd (HR, 0.72, 0.56-0.90). VRd showed superior OS, but the analysis excluded daratumumab-based regimens given immaturity of OS data. 39 The efficacy of daratumumab is also being evaluated in other PI-based doublet regimens, specifically in frail patients with NDMM.
The phase II HOVON 143 study is evaluating the efficacy of daratumumab in combination with ixazomib and low-dose dexamethasone in this subset of patients. In its first planned safety analysis, the combination was tolerated with manageable side effects. A preliminary ORR of 70% has been reported, including 20% VGPR. Updated efficacy results are awaited. 40 Ongoing trials of daratumumab-based combinations in transplant ineligible NDMM patients are listed in Table 1 ). However, both subgroups showed benefit with the daratumumab combination in terms of MRD negativity and PFS. The overall incidence of serious adverse events was similar in both groups (47% in both). There was a higher rate of grade 3-4 cytopenias in the DVTd group. Although infection rate was higher in the DVTd group, the rate of grade 3-4 infection was similar in both groups. The addition of daratumumab was associated with a lower yield of stem cells compared with VTd alone (median collected CD34+ cells 6.3 × 10 6 /kg versus 8.9 × 10 6 /kg) and increase rate of plerixafor use during mobilization. However, the rates of transplant and hematopoietic reconstitution were similar. The impact of daratumumab maintenance in patients achieving ⩾PR from both groups is currently being evaluated in another part of this study. 42 The 
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Adverse events were manageable and did not lead to death or treatment discontinuation in any patient. The trial is ongoing to assess the impact of DVRd compared with VRd alone on sCR rate. 43 Based on these initial reports, the phase III PERSUES trial was designed to compare the efficacy of DVRd to VRd in terms of PFS in this group of patients, utilizing the subcutaneous formulation of daratumumab to minimize toxicity. 44 Ongoing trials of daratumumab-based combinations in transplant eligible NDMM patients are listed in Table 2 . 41 The effect of daratumumabbased induction chemotherapy on bone marrow recovery was studied by a group at Mayo Clinic. 45 Neutrophil engraftment was found to be delayed among patients treated with daratumumab (12 patients) prior to stem cell mobilization, compared with patients who did not receive daratumumab (129 patients). Median time to engraftment was 19 and 16 days in the 2 groups, respectively (p value: 0.017). 45 As daratumumab use in the front-line setting increases, more data is needed to delineate its effect on stem cell mobilization and engraftment, and the clinical implications of these effects.
Daratumumab in NDMM irrespective of transplant eligibility
In addition to the aforementioned studies, other trials are investigating daratumumab combinations among NDMM patients, irrespective of transplant eligibility. A phase II clinical trial at Mayo Clinic was designed to evaluate the efficacy of the daratumumab in combination with ixazomib, lenalidomide and dexamethasone (D-IRd) as an induction regimen in this group of patients with a median age of 62 years 48 Ongoing trials of daratumumab-based combinations in NDMM patients irrespective of transplant eligibility are listed in Table 3 . 41
Daratumumab dosing and formulations
The currently recommended dosing of intravenous (IV) daratumumab is 16 mg/kg administered on a weekly basis for 8 weeks, then biweekly for 16 weeks, and every 4 weeks thereafter, a schedule established based on efficacy and safety data from clinical trials. 49 The pharmacokinetic properties of daratumumab were found to be unchanged when used in combination with other regimens, compared with monotherapy and regardless of the backbone regimen and of baseline patient or disease characteristics. 50 Infusion reactions related to the IV formulation of daratumumab are very commonly encountered, especially with the first dose. They have been reported at a rate between 28% and 54% in major clinical trials, with the majority being grade 1-2. 20, 23, 29, 33, 34, 42, 48 Thus, a subcutaneous (SC) formulation of daratumumab with recombinant human hyaluronidase enzyme (DARA + rHuPH20) has been developed in attempts to mitigate this reaction. Indeed, significantly decreased rates of infusion reactions have been reported with this formulation at a daratumumab dose of 1800 mg in a phase Ib safety study. 51 Subsequently, the phase III COLUMBIA trial compared the DARA + rHuPH20 SC formulation (1800 mg) with the IV formulation (16 mg/ kg) among 522 MM patients with at least 3 prior lines of therapy. The SC formulation was noninferior to the IV formulation in terms of efficacy (ORR 41% versus 37% respectively) and pharmacokinetic properties, and exhibited a similar side effect profile. More importantly, it was associated with a significantly lower rate of infusion reactions (12.7% versus 34.5% p < 0.0001), at a lower administration time. 52 As mentioned earlier, the phase III PERSUES trial is evaluating the efficacy of DVRd compared with VRd using SC daratumumab. 44 NDMM, newly diagnosed multiple myeloma; ORR, overall response rate; PO, by mouth; Pred, prednisone; Pom, pomalidomide; PT, preferred term; QD, daily; Qw, every week; SC, subcutaneous; sCR, stringent complete response; SCT, stem cell transplant; SOS, system organ class; VGPR, very good partial response. Table 3 .
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